Fractional flow reserve versus angiography in guiding management to optimize outcomes in non-ST-elevation myocardial infarction (FAMOUS-NSTEMI): rationale and design of a randomized controlled clinical trial

Colin Berry, Jamie Layland, Arvind Sood, Nick P Curzen, Kanarath P Balachandran, Raj Das, Shahid Junejo, Robert A Henderson, Andrew H Briggs, Ian Ford, Keith G Oldroyd, Colin Berry, Jamie Layland, Arvind Sood, Nick P Curzen, Kanarath P Balachandran, Raj Das, Shahid Junejo, Robert A Henderson, Andrew H Briggs, Ian Ford, Keith G Oldroyd

Abstract

Background: In patients with acute non-ST-elevation myocardial infarction (NSTEMI), coronary arteriography is usually recommended; but visual interpretation of the angiogram is subjective. We hypothesized that functional assessment of coronary stenosis severity with a pressure-sensitive guide wire (fractional flow reserve [FFR]) would have additive diagnostic, clinical, and health economic utility as compared with angiography-guided standard care.

Methods and design: A prospective multicenter parallel-group 1:1 randomized controlled superiority trial in 350 NSTEMI patients with ≥1 coronary stenosis ≥30% severity (threshold for FFR measurement) will be conducted. Patients will be randomized immediately after coronary angiography to the FFR-guided group or angiography-guided group. All patients will then undergo FFR measurement in all vessels with a coronary stenosis ≥30% severity including culprit and nonculprit lesions. Fractional flow reserve will be disclosed to guide treatment in the FFR-guided group but not disclosed in the "angiography-guided" group. In the FFR-guided group, an FFR ≤0.80 will be an indication for revascularization by percutaneous coronary intervention or coronary artery bypass surgery, as appropriate. The primary outcome is the between-group difference in the proportion of patients allocated to medical management only compared with revascularization. Secondary outcomes include the occurrence of cardiac death or hospitalization for myocardial infarction or heart failure, quality of life, and health care costs. The minimum and average follow-up periods for the primary analysis are 6 and 18 months, respectively.

Conclusions: Our developmental clinical trial will address the feasibility of FFR measurement in NSTEMI and the influence of FFR disclosure on treatment decisions and health and economic outcomes.

© 2013.

Figures

Figure 1
Figure 1
Flow diagram of the trial.
Figure 2
Figure 2
Gantt chart.

References

    1. Hamm C.W., Bassand J.P., Agewall S. ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC) Eur Heart J. 2011;32:2999–3054.
    1. Wijns W., Kolh P., Danchin N. Task force on myocardial revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS); European Association for Percutaneous Cardiovascular Interventions (EAPCI) Eur Heart J. 2010;31:2501–2555.
    1. National Institute for Clinical Excellence (NICE). Clinical guideline 94. Unstable angina and NSTEMI: the early management of unstable angina and non–ST-segment-elevation myocardial infarction (March 2010). .
    1. Selby J.V., Fireman B.H., Lundstrom R.J. Variation among hospitals in coronary-angiography practices and outcomes after myocardial infarction in a large health maintenance organization. N Engl J Med. 1996;335:1888–1896.
    1. White C.W., Wright C.B., Doty D.B. Does visual interpretation of the coronary arteriogram predicts the physiologic importance of a coronary stenosis? N Engl J Med. 1984;310:819–824.
    1. Botman K.J., Pijls N.H., Bech J.W. Percutaneous coronary intervention or bypass surgery in multivessel disease? A tailored approach based on coronary pressure measurement. Catheter Cardiovasc Interv. 2004;63:184–191.
    1. Pijls N.H., van Schaardenburgh P., Manoharan G. Percutaneous coronary intervention of functionally nonsignificant stenosis: 5-year follow-up of the DEFER Study. J Am Coll Cardiol. 2007;49:2105–2111.
    1. Tonino P.A., de Bruyne B., Pijls N.H. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention. N Engl J Med. 2009;360:213–224.
    1. De Bruyne B., Pijls N.H., Kalesan B. FAME 2 Trial Investigators. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012;367:991–1001.
    1. Fearon W.F., Bornschein B., Tonino P.A. Fractional flow reserve versus angiography for multivessel evaluation (FAME) Study Investigators. Economic evaluation of fractional flow reserve-guided percutaneous coronary intervention in patients with multivessel disease. Circulation. 2010;122:2545–2550.
    1. Pijls N.H., De Bruyne B., Peels K. Measurement of fractional flow reserve to assess the functional severity of coronary-artery stenoses. N Engl J Med. 1996;334:1703–1708.
    1. De Bruyne B., Pijls N.H., Bartunek J. Fractional flow reserve in patients with prior myocardial infarction. Circulation. 2001;104:157–162.
    1. Tonino P.A., Fearon W.F., De Bruyne B. Angiographic versus functional severity of coronary artery stenoses in the FAME study fractional flow reserve versus angiography in multivessel evaluation. J Am Coll Cardiol. 2010;55:2816–2821.
    1. Uren N.G., Crake T., Lefroy D.C. Reduced coronary vasodilator function in infarcted and normal myocardium after myocardial infarction. N Engl J Med. 1994;331:222–227.
    1. Ragosta M., Powers E.R., Samady H. Relationship between extent of residual myocardial viability and coronary flow reserve in patients with recent myocardial infarction. Am Heart J. 2001;141:456–462.
    1. Ntalianis A., Sels J.W., Davidavicius G. Fractional flow reserve for the assessment of nonculprit coronary artery stenoses in patients with acute myocardial infarction. JACC Cardiovasc Interv. 2010;3:1274–1281.
    1. Potvin J.M., Rodes-Cabau J., Bertrand O.F. Usefulness of fractional flow reserve measurements to defer revascularization in patients with stable or unstable angina pectoris, non–ST-elevation and ST-elevation acute myocardial infarction, or atypical chest pain. Am J Cardiol. 2006;98:289–297.
    1. Leesar M.A., Abdul-Baki T., Akkus N.I. Use of fractional flow reserve versus stress perfusion scintigraphy after unstable angina. Effect on duration of hospitalization, cost, procedural characteristics, and clinical outcome. J Am Coll Cardiol. 2003;41:1115–1121.
    1. Layland J., Carrick D., McEntegart M. Vasodilatory capacity of the coronary microcirculation is preserved in selected patients with non-ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv. 2013;6:231–236.
    1. Sels J.W., Tonino P.A., Siebert U. Fractional flow reserve in unstable angina and non–ST-segment elevation myocardial infarction experience from the FAME (Fractional flow reserve versus Angiography for Multivessel Evaluation) study. JACC Cardiovasc Interv. 2011;4:1183–1189.
    1. Rosner G.F., Kirtane A.J., Genereux P. Impact of the presence and extent of incomplete angiographic revascularization after percutaneous coronary intervention in acute coronary syndromes: the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. Circulation. 2012;125:2613–2620.
    1. Carrick D., Behan M., Foo F. Usefulness of fractional flow reserve to improve diagnostic efficiency in patients with non-ST elevation myocardial infarction. Am J Cardiol. 2013;111:45–50. [PMID 23040601].
    1. Pijls N.H.J., Klauss V., Siebert U. Coronary pressure measurement after stenting predicts adverse events at follow-up—a multicenter registry. Circulation. 2002;105:2950–2954.
    1. The Scottish Coronary Revascularisation Register. .
    1. Thygesen K., Alpert J.S., Jaffe A.S. Third universal definition of myocardial infarction. Circulation. 2012;126:2020–2035.
    1. Fearon W.F., Shah M., Ng M. Predictive value of the index of microcirculatory resistance in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2008;51:560–565.
    1. Payne A., Berry C., Doolin A. Microvascular resistance predicts myocardial salvage and remodeling in ST elevation myocardial infarction. JAHA. 2012;1:e002246. [PMID 23130166]
    1. Boyd K.A., Fenwick E., Briggs A. Using an iterative approach to economic evaluation in the drug development process. Drug Dev Res. 2010;71:470–477.
    1. Sculpher M.J., Claxton K., Drummond M. Whither trial-based economic evaluation for health care decision making? Health Econ. 2006;15:677–687.
    1. Guidelines for good clinical practice in clinical trials: .
    1. DAMOCLES Study Group NHS Health Technology Assessment Programme. A proposed charter for clinical trial data monitoring committees: helping them to do their job well. Lancet. 2005;365:711–722.
    1. Barrett B.J., Parfrey P.S. Clinical practice. Preventing nephropathy induced by contrast medium. N Engl J Med. 2006;354:379–386.
    1. Stone G.W., Bertrand M., Colombo A. Acute Catheterization and Urgent Intervention Triage strategY (ACUITY) trial: study design and rationale. Am Heart J. 2004;148:764–775.
Supplementary References
    1. Steigen T.K., Claudio C., Abbott D. Angiographic core laboratory reproducibility analyses: implications for planning clinical trials using coronary angiography and left ventriculography end-points. Int J Cardiovasc Imaging. 2008;24:453–462.
    1. Rongen G.A., Brooks S.C., Ando S. Caffeine abstinence augments the systolic blood pressure response to adenosine in humans. Am J Cardiol. 1998;81:1382–1385.
    1. Abidov A., Hachamovitch R., Hayes S.W. Prognostic impact of hemodynamic response to adenosine in patients older than age 55 years undergoing vasodilator stress myocardial perfusion study. Circulation. 2003;107:2894–2899.
    1. Hage F.G., Wackers F.J., Bansal S. The heart rate response to adenosine: A simple predictor of adverse cardiac outcomes in asymptomatic patients with type 2 diabetes. Int J Cardiol. 2012 doi:pii: S0167-5273(12)01025-X. 10.1016/j.ijcard.2012.08.011.
    1. Mishra R.K., Dorbala S., Logsetty G. Quantitative relation between hemodynamic changes during intravenous adenosine infusion and the magnitude of coronary hyperemia: implications for myocardial perfusion imaging. J Am Coll Cardiol. 2005;45:553–558.
    1. Amanullah A.M., Berman D.S., Kiat H. Usefulness of hemodynamic changes during adenosine infusion in predicting the diagnostic accuracy of adenosine technetium-99m sestamibi single-photon emission computed tomography (SPECT) Am J Cardiol. 1997;79:1319–1322.
    1. Goldsmith K.A., Dyer M.T., Schofield P.M. Relationship between the EQ-5D index and measures of clinical outcomes in selected studies of cardiovascular interventions. Health Qual Life Outcomes. 2009;7:96.
    1. Karamitsos T.D., Ntusi N.A., Francis J.M. Feasibility and safety of high-dose adenosine perfusion cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2010;12:66.
    1. Reyes E., Loong C.Y., Harbinson M. High-dose adenosine overcomes the attenuation of myocardial perfusion reserve caused by caffeine. J Am Coll Cardiol. 2008;52:2008–2016.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere